At the same time, a phase 3 clinical trial in ALS patients using Arimoclomol74, which is a related HSP70 inducer that had shown promise in preclinical mouse models, was terminated as it did not lead to measurable efficacy outcomes75,76. This evidence concerns the gene HSPA4 and amyotrophic lateral sclerosis.